SAB BIOTHERAPEUTICS INC (SABS) Fundamental Analysis & Valuation

NASDAQ:SABS • US78397T2024

Current stock price

3.75 USD
-0.03 (-0.79%)
At close:
3.748 USD
0 (-0.05%)
After Hours:

This SABS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. SABS Profitability Analysis

1.1 Basic Checks

  • In the past year SABS has reported negative net income.
  • In the past year SABS has reported a negative cash flow from operations.
  • SABS had negative earnings in 4 of the past 5 years.
  • In the past 5 years SABS reported 4 times negative operating cash flow.
SABS Yearly Net Income VS EBIT VS OCF VS FCFSABS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 0 20M -20M -40M

1.2 Ratios

  • SABS has a better Return On Assets (-7.42%) than 84.26% of its industry peers.
  • Looking at the Return On Equity, with a value of -8.46%, SABS belongs to the top of the industry, outperforming 87.72% of the companies in the same industry.
Industry RankSector Rank
ROA -7.42%
ROE -8.46%
ROIC N/A
ROA(3y)-41.66%
ROA(5y)-36.58%
ROE(3y)-67.38%
ROE(5y)-61.39%
ROIC(3y)N/A
ROIC(5y)N/A
SABS Yearly ROA, ROE, ROICSABS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 0 50 -50 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SABS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SABS Yearly Profit, Operating, Gross MarginsSABS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. SABS Health Analysis

2.1 Basic Checks

  • SABS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for SABS has been increased compared to 1 year ago.
  • Compared to 5 years ago, SABS has more shares outstanding
  • The debt/assets ratio for SABS has been reduced compared to a year ago.
SABS Yearly Shares OutstandingSABS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
SABS Yearly Total Debt VS Total AssetsSABS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • SABS has an Altman-Z score of 4.18. This indicates that SABS is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 4.18, SABS is doing good in the industry, outperforming 72.36% of the companies in the same industry.
  • A Debt/Equity ratio of 0.02 indicates that SABS is not too dependend on debt financing.
  • SABS's Debt to Equity ratio of 0.02 is in line compared to the rest of the industry. SABS outperforms 45.30% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 4.18
ROIC/WACCN/A
WACC8.99%
SABS Yearly LT Debt VS Equity VS FCFSABS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 9.46 indicates that SABS has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 9.46, SABS is doing good in the industry, outperforming 79.08% of the companies in the same industry.
  • A Quick Ratio of 9.46 indicates that SABS has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 9.46, SABS is doing good in the industry, outperforming 79.08% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.46
Quick Ratio 9.46
SABS Yearly Current Assets VS Current LiabilitesSABS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. SABS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 42.45% over the past year.
  • SABS shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -60.74% yearly.
  • Looking at the last year, SABS shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)42.45%
EPS 3YN/A
EPS 5Y-60.74%
EPS Q2Q%71.45%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • The Earnings Per Share is expected to grow by 18.11% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y71.06%
EPS Next 2Y33.31%
EPS Next 3Y22.09%
EPS Next 5Y18.11%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SABS Yearly Revenue VS EstimatesSABS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
SABS Yearly EPS VS EstimatesSABS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

1

4. SABS Valuation Analysis

4.1 Price/Earnings Ratio

  • SABS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SABS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SABS Price Earnings VS Forward Price EarningsSABS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SABS Per share dataSABS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SABS's earnings are expected to grow with 22.09% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.31%
EPS Next 3Y22.09%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SABS Dividend Analysis

5.1 Amount

  • SABS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SABS Fundamentals: All Metrics, Ratios and Statistics

SAB BIOTHERAPEUTICS INC

NASDAQ:SABS (3/20/2026, 8:21:51 PM)

After market: 3.748 0 (-0.05%)

3.75

-0.03 (-0.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-09
Earnings (Next)05-07
Inst Owners75.21%
Inst Owner Change28.02%
Ins Owners1.87%
Ins Owner Change13.15%
Market Cap191.06M
Revenue(TTM)N/A
Net Income(TTM)-12.82M
Analysts85.71
Price Target9.56 (154.93%)
Short Float %3.78%
Short Ratio3.28
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.86%
Min EPS beat(2)-72.65%
Max EPS beat(2)70.94%
EPS beat(4)2
Avg EPS beat(4)2.68%
Min EPS beat(4)-72.65%
Max EPS beat(4)70.94%
EPS beat(8)4
Avg EPS beat(8)9.62%
EPS beat(12)6
Avg EPS beat(12)-35.01%
EPS beat(16)10
Avg EPS beat(16)-14.1%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)6.13%
EPS NQ rev (1m)-23.99%
EPS NQ rev (3m)-10.58%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.26
P/tB 1.26
EV/EBITDA N/A
EPS(TTM)-2.15
EYN/A
EPS(NY)-0.62
Fwd EYN/A
FCF(TTM)-0.9
FCFYN/A
OCF(TTM)-0.88
OCFYN/A
SpS0
BVpS2.97
TBVpS2.97
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.42%
ROE -8.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-41.66%
ROA(5y)-36.58%
ROE(3y)-67.38%
ROE(5y)-61.39%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.28%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.46
Quick Ratio 9.46
Altman-Z 4.18
F-Score3
WACC8.99%
ROIC/WACCN/A
Cap/Depr(3y)14.24%
Cap/Depr(5y)169.21%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.45%
EPS 3YN/A
EPS 5Y-60.74%
EPS Q2Q%71.45%
EPS Next Y71.06%
EPS Next 2Y33.31%
EPS Next 3Y22.09%
EPS Next 5Y18.11%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-63.2%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-31.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-30.57%
OCF growth 3YN/A
OCF growth 5YN/A

SAB BIOTHERAPEUTICS INC / SABS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SAB BIOTHERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to SABS.


What is the valuation status for SABS stock?

ChartMill assigns a valuation rating of 1 / 10 to SAB BIOTHERAPEUTICS INC (SABS). This can be considered as Overvalued.


What is the profitability of SABS stock?

SAB BIOTHERAPEUTICS INC (SABS) has a profitability rating of 2 / 10.


What is the earnings growth outlook for SAB BIOTHERAPEUTICS INC?

The Earnings per Share (EPS) of SAB BIOTHERAPEUTICS INC (SABS) is expected to grow by 71.06% in the next year.